This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iwamoto, M.
Right arrow Articles by Pickering, L. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iwamoto, M.
Right arrow Articles by Pickering, L. K.
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Rotavirus Infections
PEDIATRICS Vol. 112 No. 1 July 2003, pp. e6-e10

ELECTRONIC ARTICLE

A Survey of Pediatricians on the Reintroduction of a Rotavirus Vaccine

Martha Iwamoto, MD, MPH*, Thomas N. Saari, MD{ddagger}, Shawn R. McMahon, MD, MPH§, Hussain R. Yusuf, MBBS, MPH§, Mehran S. Massoudi, PhD, MPH§, John M. Stevenson, MA§, Susan Y. Chu, PhD, MSPH§ and Larry K. Pickering, MD§

* Rollins School of Public Health, Emory University, Atlanta, Georgia
{ddagger} University of Wisconsin Children’s Hospital, Madison, Wisconsin
§ National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia

Objective. Rhesus-based rotavirus tetravalent vaccine (RRV-TV; RotaShield) was withdrawn voluntarily from the market in October 1999, and recommendations for use were suspended. Rotavirus infection continues to be a significant health problem affecting children worldwide. The objective of this study was to investigate whether pediatricians would either reconsider using RRV-TV or consider other, newer, and presumably safer rotavirus vaccines if they were recommended routinely and to determine factors that influence their opinion.

Methods. A questionnaire was sent to a random sample of 250 members of the Wisconsin Chapter of the American Academy of Pediatrics (AAP) and to 437 randomly selected members of the Georgia Chapter of the AAP. Nonresponders received reminder questionnaires.

Results. Of the 687 pediatricians surveyed, 384 (56%) responded. Responses from 319 eligible immunization providers were included in the final analysis. Although only 15% of respondents reported that they would give RRV-TV if it were available today, 94% reported that they would use a new rotavirus vaccine if proved to be safer than RRV-TV and if recommended by the AAP and Advisory Committee on Immunization Practices for routine use among infants. Barriers to reintroducing a rotavirus vaccine were fear of adverse reactions among 95% of pediatricians, followed by potential high vaccine cost (63%) and amount of time required to educate parents (57%).

Conclusions. Pediatricians reported that they would use a rotavirus vaccine if it was safer than RRV-TV and routinely recommended by the AAP and the Advisory Committee on Immunization Practices.

Key Words: rotavirus • rotavirus vaccine • RRV-TV

Abbreviations: RRV-TV, rhesus-based rotavirus tetravalent vaccine • AAP, American Academy of Pediatrics • ACIP, Advisory Committee on Immunization Practices

Received for publication Jun 13, 2002; Accepted Mar 13, 2003.




This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
L. M. Jacobson, M. Santosham, and A. M. Milstone
Pediatric Providers' Acceptance of Recommendations for Routine Rotavirus Vaccination
Clinical Pediatrics, June 1, 2008; 47(5): 500 - 503.
[PDF]

Home page
 AAP Grand RoundsHome page
M. H. Rathore and L. L. Barton
Rotavirus Vaccines Are Safe and Effective
AAP Grand Rounds, April 1, 2006; 15(4): 37 - 38.
[Full Text] [PDF]